Savara, Inc. (SVRA)

[Roadtojourney]

Yup sell on news pos

[Sage7243]

So...looks like the co. is funded. Yes!!!

[davidsson10]

Well, the ol' Balls O' Steel deliver another double. Yet, I don't know if this ticker has another round left in it, or not.....

SVRA

[davidsson10]

Yes, saw that earlier.....

[crudeoil24]

Savara Announces Private Placement of $26.8 Million, With Total Potential Proceeds of $75.0 Million .
11:51 am ET December 20, 2019 (BusinessWire) Print
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it has entered into a definitive agreement for a private placement with institutional investors to purchase an aggregate of 9,569,430 shares of common stock and, in lieu of shares of common stock, pre-funded warrants to purchase an aggregate of 5,780,537 shares of common stock, and accompanying warrants (the "Milestone Warrants") to purchase an aggregate of up to 32,577,209 additional shares of common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a price of $1.745 per share and accompanying Milestone Warrant (or $1.744 per pre-funded warrant and accompanying Milestone Warrant). The price per pre-funded warrant and accompanying Milestone Warrant represents the price of $1.745 per share and accompanying Milestone Warrant to be sold in the private placement, minus the $0.001 per share exercise price of each such pre-funded warrant. The exercise price of the Milestone Warrants is $1.48 per share, or if exercised for a pre-funded warrant in lieu thereof, $1.479 per pre-funded warrant (representing the Milestone Warrant exercise price of $1.48 per share minus the $0.001 per share exercise price of each such pre-funded warrant). The Milestone Warrants are exercisable at any time prior to the earlier of 30 days following the achievement of a defined clinical milestone or two years after the closing date of the private placement. The gross proceeds from the sales of common stock and pre-funded warrants are expected to be $26.8 million, before deducting placement agent fees and estimated offering expenses payable by Savara. If the Milestone Warrants are exercised in full, Savara would receive additional gross proceeds of $48.2 million, resulting in total transaction gross proceeds of $75.0 million, in each case before deducting placement agent fees and estimated offering expenses payable by Savara. The private placement, led by Bain Capital Life Sciences, with participation by certain existing and new investors, including EcoR1 Capital LLC and Logos Capital, is expected to close on December 24, 2019, subject to customary closing conditions. In connection with the closing, Ricky Sun, Ph.D. of Bain

[Liquid1974]

Added

[ClayTrader]

* * $SVRA Video Chart 11-29-2019 * *

Link to Video - click here to watch the technical chart video

[boston127]

Please post the URL for presentation.

TIA.

[AlanF]

I just read the Stifel presentation. They missed success by one patient.
Wow. Too small a trial.

[stock1ace1]

Hod break @.94 watch

[stock1ace1]

New CMO worked for FDA for 16 years + he came from AstraZeneca (AZN) trading at 47$ a share

This is exciting news for shareholders


Dr. Chowdhury joins Savara from AstraZeneca, where he was Senior Vice President, Chief Physician-Scientist for Respiratory, Inflammation, and Autoimmunity Late Stage Development, in Biopharmaceuticals R&D. For 16 years prior to that, Dr. Chowdhury served as Director, Division of Pulmonary, Allergy, and Rheumatology Products, Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) where he provided scientific and regulatory oversight of both common and rare diseases such as asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, rheumatoid arthritis, systemic lupus erythromatosis, and various autoimmune and inflammatory diseases. Dr. Chowdhury is a medical doctor, and also holds a Ph.D. in Immunology. He completed Internal Medicine residency training from the Wayne State University School of Medicine, Detroit, Michigan, and Fellowship training in Allergy and Immunology from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, Maryland. He is double board certified in Internal Medicine and Allergy and Immunology.

[stock1ace1]

*** There Presenting Tomorrow ~> Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, will be presenting at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:00 PM ET / 12:00 PM PT at the Lotte New York Palace Hotel. Rob Neville, Savara’s Chief Executive Officer, will represent the Company at the conference.

[hb90]

It's a shame a company trying to do good in the world tanking like this. Sure hope they pull through. Something like this is more then just making a buck

[AlanF]

The data for Impala should get better during the open label time period, based on the literature. In a way, the later the FDA meeting the better. I believe it is scheduled for October.

[Leonard McKinley]

A take over of this company is highly unlikely IMO. It is just not that important.

[m0n]

$SVRA buyout candidate?

Price is cheap even at $7 acquisition with its pipeline

ALL IMO

[pray]

Have you looked lately?

Buy Time?

[Boneride]

2.27 close tomorrow. What a powerhouse !

[Boneride]

svra a joke

[Boneride]

As usual, Mr. M., you are correct and I suck. I took a SEEL shellacking and I'm hoping to get at least SOME of it back with SVRA. So what happens just one day after my miserable, little post ? SVRA up to 2.79 AH, with plenty of room to move. Just trying to succeed at one (legal) thing in my life before my eternal dirt nap. You're a nice man.

[Leonard McKinley]

Bone: Yo are not patient. Look today. Savara had a good report today at the conference. All is not lost.

[Boneride]

SEEL and SVRA can both be found at the bottom of the same dumpster.

[m0n]

“Most importantly, the impressive improvement in quality of life, as measured by the SGRQ, suggest that Molgradex not only improved objective measures of oxygenation, but also had a clinically meaningful therapeutic effect. I believe these data demonstrate that Molgradex can become an important pharmacological treatment option for patients with aPAP.”

$SVRA $MSTVW

https://t.co/wHzSricdVX

[Leonard McKinley]

The rest of the pipeline is of course interesting, but the market only cares about the immediate issue. It will take quite some time for anything to manifest itself from the rest of the pipeline and that means dilution. The market wants a prompt solution to this present problem in order to rally the stock. IMO

[m0n]

Lets not forget the other pipeline too

[Leonard McKinley]

Savara is presenting at the JP Morgan conference on this coming Wednesday. I think it will be important to listen to what they have to say further about the P3 as they have now had a week to think about it. I am particularly interested in their thoughts about the "unusually" high placebo effect. How can a placebo effect be unusually high? What might be the explanation for that? What might it mean about possible paths forward for a drug that seems to have worked?
Was this group an unusually optimistic group? Are the psychological impacts on lung conditions greater than the psychological impact on other bodily functions? I have no clue, but if there is an answer it could be very important to the future of the drug.

[m0n]

Phase III wasn’t failed, if you read the news there was improvement, just not as high. Its not like the drug didn’t work, hence failure.

[Leonard McKinley]

Brilliant remark: It could go up.....or it could go down. Thank you for that....very astute.

[ttrader707]

On watch, could bounce $$$

$SVRA

[ClayTrader]

* * $SVRA Video Chart 06-13-2019 * *

Link to Video - click here to watch the technical chart video

[Green_gold]

More or less failed phase 3 results.

[mauiguy2]

I've been watching this stock from afar.

And if you want to know when shorts are on something look for midpoint orders like $2.595 or $2.605

KOmani, I don't understand your example. I haven't heard this previously. Can you briefly explain how it works? Thanks.

[KOmani]

And if you want to know when shorts are on something look for midpoint orders like $2.595 or $2.605

That's them making sure the price doesn't go wild.

[KOmani]

Shorts have stomped any potential run.

Even if it is on the SSR list, it means nothing.

Far more shorts today than ever before.

[mcgbyron]

What happened?

[QaB2i]

Dead cat bounce?

[nicky2000]

Ouch... down 75%

[tymerz]

Savara beats by $0.03 Cash and equivalents of $105.2M.

https://seekingalpha.com/news/3462099-savara-beats-0_03

Warrants MSTVW gonna fly!

GLTA!!!

[tymerz]

Results https://flashalert.me/?symbol=SVRA&source=PR&referer=https://stocktwits.com/&url=http://www.businesswire.com/news/home/20190509005813/en/Savara-Reports-Quarter-2019-Financial-Results-Business/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa&s3=SVRA/2019-05-09/20-05-26_017502/bw/?feedref=JjAwJuNHiystnCoBq_hl-bV7DTIYheT0D-1vT4_bKFzt_EW40VMdK6eG-WLfRGUE1fJraLPL1g6AeUGJlCTYs7Oafol48Kkc8KJgZoTHgMu0w8LYSbRdYOj2VdwnuKwa


GLTA!

[tymerz]

HUGE NEWS! https://www.globalbankingandfinance.com/savara-announces-molgradex-received-fast-track-designation-by-fda-for-treatment-of-autoimmune-pulmonary-alveolar-proteinosis/

GLTA!!!

[tymerz]

Molgradex Receives Fast Track Designation for Treatment of Autoimmune Pulmonary Alveolar Proteinosis.

This is an autoimmune lung disorder. Fast tracking this is HUGE news!!!

GLTA!!!

[jonnyvs]

Huge news!

[tymerz]

Savara Inc. beats on 5 of the 6 factors Odonate Therapeutics Inc. Savara and Odonate Therapeutics - https://cryptocoinstribune.com/savara-inc-svra-and-odonate-therapeutics-inc-nasdaqodt-comparing-side-by-side/

GLTA!

[tymerz]

Here we go again! SVRA up at highs, warrants MSTVW about to explode.

GLTA!!!

[shanak10]

https://www.businesswire.com/news/home/20190502005189/en/Savara-Report-Quarter-2019-Financial-Results-Provide

[DIVEROTC1]

Why so quiet?

[DIVEROTC1]

I’m not sure it will dip that low again

[pray]

Look at date ... way back in summer of 2017. Sunk below $6.00. Bought at $5.75 sold around $11.00. Have not bought since. Was waiting for under 6 again.

[DIVEROTC1]

Huh?

[DIVEROTC1]

Think so?